Detalles de la búsqueda
1.
Long-term safety and efficacy of subcutaneous pasireotide in patients with Cushing's disease: interim results from a long-term real-world evidence study.
Pituitary
; 22(5): 542-551, 2019 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-31440946
2.
Multicenter validation of spin-density projection-assisted R2-MRI for the noninvasive measurement of liver iron concentration.
Magn Reson Med
; 71(6): 2215-23, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23821350
3.
Activity and safety of eltrombopag in combination with cyclosporin A as firstline treatment of adults with severe aplastic anaemia (SOAR): a phase 2, single-arm study.
Lancet Haematol
; 11(3): e206-e215, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38335978
4.
Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with ß-thalassaemia: results from the ESCALATOR study.
Eur J Haematol
; 87(4): 349-54, 2011 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-21668501
5.
Importance of optimal dosing ≥ 30 mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with ß-thalassaemia.
Eur J Haematol
; 87(4): 355-65, 2011 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-21668502
6.
Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with beta-Thalassemia: Results from the ESCALATOR Trial.
Acta Haematol
; 123(4): 220-5, 2010.
Artículo
en Inglés
| MEDLINE | ID: mdl-20424435
7.
Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia.
Eur J Haematol
; 82(6): 454-7, 2009 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-19191863
8.
Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study.
Eur J Haematol
; 82(6): 458-65, 2009 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-19187278
9.
Phase I, open-label study of pasireotide in patients with BRAF-wild type and NRAS-wild type, unresectable and/or metastatic melanoma.
ESMO Open
; 3(5): e000388, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30094073
Resultados
1 -
9
de 9
1
Próxima >
>>